Clinical Trials Logo
  1. Home
  2. Head & Neck Cancer
  3. NCT05838729

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Head Neck Cancer Clinical Trial

Official title:
Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer

Clinical Trial Summary

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.

Clinical Trial Description

Primary Objectives: - To determine the tolerability of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor (pembrolizumab or nivolumab) in patients with unresectable, recurrent or metastatic head-neck cancer - To determine the efficacy of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor (pembrolizumab or nivolumab) Secondary Objectives: - To evaluate progression-free survival for up to 12 months - To determine overall survival for up to 24 months - To assess patient quality of life The target population is patients with unresectable, recurrent or metastatic head-neck cancer which is clinically accessible to intratumoral injection. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05838729
Study type Interventional
Source Coordination Pharmaceuticals, Inc.
Contact Ze-Qi Xu
Phone 630-415-5601
Email zq@coordinationpharma.com
Status Recruiting
Phase Phase 1/Phase 2
Start date April 3, 2023
Completion date December 1, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Terminated NCT02521870 - A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02268344 - Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection N/A
Terminated NCT00198328 - Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma Phase 3
Recruiting NCT04858269 - First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Phase 2
Recruiting NCT05878964 - Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
Recruiting NCT03051269 - Calcium Electroporation for Head and Neck Cancer Phase 1
Completed NCT05833841 - Swallowing Function in Patients With Head and Neck Cancers N/A
Withdrawn NCT03747562 - Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients. Phase 3
Completed NCT03572829 - Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC Phase 2
Completed NCT02075385 - Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer Phase 2
Recruiting NCT02549742 - Electrochemotherapy on Head and Neck Cancer Phase 2
Completed NCT01951664 - Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors N/A
Completed NCT03832686 - Investigation of Two Swallowing Therapy Models During Radiation Therapy for Head and Neck Cancer N/A
Recruiting NCT05382585 - Newer Therapeutic Targets in Head and Neck Cancers